WHITE PAPER

Hereditary ATTR Amyloidosis: Voice of the Patient

Hereditary transthyretin amyloidosis (ATTRv) is a progressive, life-threatening disease that damages the heart, nerves, and other organs. The past decade has brought remarkable advances including multiple new disease-modifying therapies. Yet for many patients, that progress remains out of reach.

This white paper combines insights from Genome Medical’s nationwide cohort of patients with ATTRv and peer-reviewed literature to highlight gaps and opportunities in care with implications for clinical research, drug development, and patient access to emerging therapies.

The paper explores:

Download the paper below to explore:

• Diagnostic delays and the path to an ATTR diagnosis
  
• The genetic testing and cascade testing gap
• Treatment access amid rapidly evolving therapeutics
• What earlier diagnosis and disease-modifying therapy mean for ATTR trial design